Navigation Links
Xanodyne Announces New Executive Team Members

NEWPORT, Ky., July 13 /PRNewswire/ -- Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management, today announced the appointment of three new members to its executive management team. Joining the company are Natasha Giordano, Chief Commercial Officer; Rita O'Connor, Chief Financial & Information Officer; and Peter Wentworth, Senior Vice President, Human Resources.

Commenting on these appointments, CEO Michael J. Valentino said, "I am excited to welcome Natasha, Rita, and Peter to the Xanodyne management team. Each of them brings a diverse and proven track record of building and leading high growth organizations within the pharmaceutical industry. Their collective experience should contribute significantly to the anticipated rapid growth and commercial success of our company."

Ms. Giordano has more than 25 years of experience in the healthcare and pharmaceutical industry and most recently served as President Americas at Cegedim Dendrite, a global sales and marketing solutions and information company specializing in the pharmaceutical industry. Her depth of experience includes senior leadership positions in general management, marketing, compliance, and sales at major pharmaceutical companies including Pfizer and Parke-Davis.

Ms. O'Connor joins Xanodyne from NPS Pharmaceuticals where she served as Vice President, Finance. Previously, she was Chief Financial Officer and Treasurer at Adams Respiratory Therapeutics. With nearly 20 years of finance and accounting experience in the pharmaceutical industry, O'Connor is a certified public accountant and has held leadership positions at Schering-Plough and Deloitte & Touche. She also serves on the Board of Directors at the Essential Group Inc.

Mr. Wentworth has extensive experience within the field of human resources, including more than 25 years working in global healthcare and consumer products industries. Most recently he was Executive Vice President, Human Resources at Adams Respiratory Therapeutics. Wentworth is a seasoned business leader, who has held a broad range of positions at major global companies such as Pfizer, Warner-Lambert, and PepsiCo.

About Xanodyne
Xanodyne Pharmaceuticals, Inc., which commenced operations in 2001, is an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management. Xanodyne markets a portfolio of products consisting of FDA approved pharmaceuticals and a line of prenatal vitamins. Additionally, Xanodyne is advancing a late stage pipeline of product candidates targeted at significant potential markets in Xanodyne's focus areas.

SOURCE Xanodyne Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2009 Earnings Release and Conference Call
2. Jesup & Lamont Announces Presenting LifeTech Companies and Former FDA Commissioner at Annual Growth Stock & National Sales Conference
3. Boston Scientific Announces European Approval for Its LATITUDE(R) Patient Management System
4. MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus
5. China-Biotics, Inc. Announces Conference Call to Discuss Fourth Quarter and Full Year 2009 Financial Results
6. Mirixa Corporation Announces Key New Hires
7. Harvest Technologies Announces Completion of Patient Enrollment in its 60 Patient Clinical Trial in India Using Autologous Adult Stem Cells to Treat Patients With Non-Reconstructable Critical Limb Ischemia
8. Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity
9. Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments
10. DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology
11. Tianyin Pharmaceutical Co., Inc. Announces Cash Dividend to Common Stockholders
Post Your Comments:
(Date:11/25/2015)... 2015  PharmAthene, Inc. (NYSE MKT: PIP) announced  today ... rights plan (Rights Plan) in an effort to preserve ... under Section 382 of the Internal Revenue Code (Code). ... use of its NOLs could be substantially limited if ... Section 382 of the Code. In general, an ownership ...
(Date:11/25/2015)... 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... CEO of Neurocrine Biosciences, will be presenting at the ... New York . .   ... 5 minutes prior to the presentation to download or ... will be available on the website approximately one hour ...
(Date:11/25/2015)... 2015 The Global Genomics ... professional and in-depth study on the current state ... ) , The report ... definitions, classifications, applications and industry chain structure. The ... markets including development trends, competitive landscape analysis, and ...
(Date:11/24/2015)... Calif. , Nov. 24, 2015 Cepheid ... will be speaking at the following conference, and invited ... New York, NY      Tuesday, December 1, 2015 ... New York, NY      Tuesday, December 1, 2015 ... Jaffray Healthcare Conference, New York, NY ...
Breaking Biology Technology:
(Date:11/12/2015)...  Arxspan has entered into an agreement with ... use of its ArxLab cloud-based suite of biological ... will support the institute,s efforts to electronically manage ... internally and with external collaborators. The ArxLab suite ... Institute,s electronic laboratory notebook, compound and assay registration, ...
(Date:11/10/2015)... , Nov. 10, 2015  In this ... the basis of product, type, application, disease ... in this report are consumables, services, software. ... are safety biomarkers, efficacy biomarkers, and validation ... report are diagnostics development, drug discovery and ...
(Date:11/9/2015)...  Synaptics Inc. (NASDAQ: SYNA ), the leading ... into the automotive market with a comprehensive and dedicated ... consumer electronics human interface innovation. Synaptics, industry-leading touch controllers, ... automotive industry and will be implemented in numerous locations ... , Japan , and ...
Breaking Biology News(10 mins):